Rituximab-Induced Serum Sickness in a Seven-Year-Old Child With Nephrotic Syndrome.

Area of Science:

• Pediatric Nephrology
• Pharmacovigilance
• Immunology

Background:

• Steroid-dependent nephrotic syndrome (SDNS) in children often requires advanced treatments.
• Rituximab, a monoclonal antibody, shows promise in managing frequent relapses of SDNS.
• Limited data exists on rituximab's adverse effects in pediatric populations.

Observation:

• A seven-year-old boy with SDNS developed fever and severe polyarthralgia 13 days post-rituximab.
• Symptoms were self-limiting, and other causes were excluded.
• This presentation aligns with a potential diagnosis of serum sickness.

Findings:

• The case suggests rituximab-induced serum sickness as a possible adverse reaction in pediatric SDNS.
• The temporal association and clinical features support this diagnosis.
• This highlights an unusual side effect of rituximab in a pediatric patient.

Implications:

• Clinicians should be aware of the potential for rituximab-induced serum sickness in children.
• Pharmacovigilance data is crucial for understanding rare adverse events in pediatric drug use.
• Further research is needed to define rituximab's safety profile in pediatric nephrotic syndrome.